PremiumRatingsBicycle Therapeutics: Promising Advancements and Strong Financial Position Justify Buy Rating Promising Developments in Bicycle Therapeutics’ Pipeline Bolster Buy Rating Bicycle Therapeutics reports Q1 EPS (88c), consensus (81c) PremiumThe FlyBicycle names Pierre Legault chairman, Eric Westin chief medical officer Promising Upside for Bicycle Therapeutics: Buy Rating Backed by Positive Clinical Data and Market Potential for ZP Treatment Bicycle Therapeutics: Promising Pipeline Progress and Expansion Opportunities Drive Buy Rating PremiumRatingsBicycle Therapeutics: Promising Clinical Advances and Strong Financial Position Support Buy Rating Bicycle Therapeutics price target lowered to $42 from $53 at Jefferies Bicycle Therapeutics reports Q4 EPS (75c), consensus (85c) 
